Exon Publications, located in Australia, publishes peer-reviewed, open access books in the fields of health and biomedical sciences. Our books are indexed in NCBI/NIH/NLM Bookshelf, PubMed, Europe PubMed Central and Web of Science.

 

Web of Science

 

Exon Publications abides by the Principles of Transparency and Best Practice in Scholarly Publishing, and is a member of the International Association of Scientific, Technical and Medical Publishers (STM) and the Association of Learned and Professional Society Publishers (ALPSP).  

 

 

Our Authors: Researchers from reputed institutions have published with us. The complete list is available here.

 

YaleTexas UW

McGill

Lisbon

Spain

 

Our Editors: Experts from the following institutes have edited books for us. The complete list is available here

 

HarvardMGHNYU

Cambridge

 

 

Alzheimer's Disease: Drug Discovery

ALZHEIMER's DISEASE: DRUG DISCOVERY
ISBN: 978-0-6450017-0-9
Exon Publications, Brisbane, Australia

Xudong Huang, PhD (Ed)
Neurochemistry Laboratory, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA

 

Alzheimer’s disease is the most common cause of age-related dementia. Alzheimer’s disease presents with irreversible cognitive decline, which commences as insidious short-term memory dysfunction and gradually spreads to other cognitive domains, rendering patients mute and non-ambulatory after 10-15 years of progressive course. Unfortunately, there are neither effective preventive measures nor efficacious treatments available for this devastating disease. Such a situation undoubtedly calls for the diversification of druggable targets for Alzheimer’s disease and a search for poly-targets or drug combination therapeutic strategies. Contributed by an assembly of clinicians and translational and basic research scientists, this book intends to provide an overview of the current state and future perspectives of Alzheimer’s disease drug discovery. It covers the underlying pathogenic mechanisms of Alzheimer’s disease and provides a review of Aβ amyloid- and τ protein-targeted immunotherapies, and peptide inhibitors for anti-Aβ amyloidosis. In addition, it also examines therapeutic potentials of various Alzheimer’s disease drug targets such as brain metal homeostasis, protein kinase C, the blood-brain barrier, epigenetic therapies, as well as discusses chimeric conjugates, multifunctional ligands, and natural products as interventional approaches. This book will be valuable to healthcare professionals caring for patients, researchers and interested readers as it will provoke thoughts about identifying novel and more efficacious therapeutic agents for Alzheimer’s disease and related dementias.

Published: 2020-12-19

Foreword

Martin J. Sadowski

Pages vii-viii

Preface

Xudong Huang

Pages ix-x

Amyloid β-Targeted Inhibitory Peptides for Alzheimer’s Disease: Current State and Future Perspectives

Safura Jokar, Saeedeh Khazaei, Xaniar Esmailzadeh Gameshgoli, Mona Khafaji, Behnam Yarani, Mohammad Sharifzadeh, Davood Beiki, Omid Bavi

Pages 51-68

Targeting Metal Homeostasis as a Therapeutic Strategy for Alzheimer’s Disease

Antonietta Vilella, Eleonora Daini, Chiara De Benedictis, Andreas Grabrucker

Pages 83-98

Modeling the Blood–Brain Barrier to Understand Drug Delivery in Alzheimer’s Disease

Joanna M Wasielewska, Juliana C Da Silva Chaves, Anthony R White, Lotta Oikari

Pages 117-134

Chimeric Conjugates for Alzheimer’s Disease

Illham Dhala, Tabassum Khan, Arati Prabhu

Pages 165-180

Natural Products for Neurocognitive Disorders

Adriana Servello, Vincenzo Leccese, Evaristo Ettorre

Pages 205-220

Index

Pages 221-229

View All Books